Abstract

BackgroundVariability in drug response between individual patients is a serious concern in medicine. To identify single-nucleotide polymorphisms (SNPs) related to drug response variability, many genome-wide association studies have been conducted.MethodsWe previously applied a knowledge-based bioinformatic approach to a pharmacogenomics study in which 119 fluoropyrimidine-treated gastric cancer patients were genotyped at 109,365 SNPs using the Illumina Human-1 BeadChip. We identified the SNP rs2293347 in the human epidermal growth factor receptor (EGFR) gene as a novel genetic factor related to chemotherapeutic response. In the present study, we reanalyzed these hypothesis-free genomic data using extended knowledge.ResultsWe identified rs2867461 in annexin A3 (ANXA3) gene as another candidate. Using logistic regression, we confirmed that the performance of the rs2867461 + rs2293347 model was superior to those of the single factor models. Furthermore, we propose a novel integrated predictive index (iEA) based on these two polymorphisms in EGFR and ANXA3. The p value for iEA was 1.47 × 10−8 by Fisher’s exact test. Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway.ConclusionsThese results suggest that the iEA index or a combination of polymorphisms in EGFR and ANXA3 may serve as predictive factors of drug response, and therefore could be useful for optimal selection of chemotherapy regimens.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1721-z) contains supplementary material, which is available to authorized users.

Highlights

  • Variability in drug response between individual patients is a serious concern in medicine

  • Dihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene, plays a key role in the adverse effects of fluoropyrimidine treatment: it participates in the catabolism of fluoropyrimidines, such as 5-fluorouracil (5-FU) and its prodrugs capecitabine and S-1

  • We found that rs2293347 in the human epidermal growth factor receptor (EGFR) is a candidate single-nucleotide polymorphisms (SNPs) related to chemotherapeutic response and antitumor effect

Read more

Summary

Introduction

Variability in drug response between individual patients is a serious concern in medicine. To identify single-nucleotide polymorphisms (SNPs) related to drug response variability, many genome-wide association studies have been conducted. Inter-individual variation in drug response is clinically expected, but relatively difficult to predict [1, 2]. Genetic variation is an important cause of inter-individual variability in drug response. Dihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene, plays a key role in the adverse effects of fluoropyrimidine treatment: it participates in the catabolism of fluoropyrimidines, such as 5-fluorouracil (5-FU) and its prodrugs capecitabine and S-1 (trade name TS-1, the 5-fluorouracil derivative developed by Tetsuhiko Shirasaka). DPD is an inactivating and rate-limiting enzyme for 5-FU, which is used in various chemotherapeutic regimens to treat gastrointestinal, breast, and head/neck cancers [3]. DPD affects 5-FU availability by rapidly degrading it to 5,6-dihydrofluorouracil (DHFU) [4]. 5-FU catabolism occurs in various tissues including tumors, but is most active in the liver [5, 6]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call